NASDAQ:ATEC - Alphatec Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.50
  • Forecasted Upside: 10.89 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$14.88
▲ +0.14 (0.95%)

This chart shows the closing price for ATEC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alphatec Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATEC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATEC

Analyst Price Target is $16.50
▲ +10.89% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Alphatec in the last 3 months. The average price target is $16.50, with a high forecast of $20.00 and a low forecast of $12.00. The average price target represents a 10.89% upside from the last price of $14.88.

This chart shows the closing price for ATEC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Alphatec. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/9/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/7/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2021Canaccord GenuityReiterated RatingBuyLow
3/5/2021Piper SandlerBoost Price TargetOverweight$17.00 ➝ $19.00High
3/5/2021HC WainwrightBoost Price TargetBuy$16.00 ➝ $19.00High
1/29/2021Piper SandlerBoost Price TargetOverweight$12.00 ➝ $17.00Low
1/13/2021Canaccord GenuityReiterated RatingBuy$16.00Low
12/21/2020HC WainwrightReiterated RatingBuy$12.00 ➝ $16.00High
12/18/2020Lake Street CapitalBoost Price Target$15.00 ➝ $20.00High
12/18/2020Canaccord GenuityBoost Price TargetBuy$12.00 ➝ $16.00High
10/19/2020Stifel NicolausInitiated CoverageBuy$13.00Medium
10/12/2020HC WainwrightBoost Price TargetBuy$9.00 ➝ $12.00Low
10/8/2020Lake Street CapitalBoost Price TargetBuy$13.00 ➝ $15.00High
10/8/2020Canaccord GenuityBoost Price TargetPositive ➝ Buy$9.00 ➝ $12.00High
9/3/2020CowenInitiated CoverageOutperform$12.00High
8/13/2020Canaccord GenuityReiterated RatingBuy$9.00Low
8/7/2020Canaccord GenuityReiterated RatingBuy$9.00High
6/18/2020Northland SecuritiesInitiated CoverageOutperform$9.00Medium
4/9/2020HC WainwrightReiterated RatingBuy$9.50 ➝ $7.50Medium
3/6/2020HC WainwrightReiterated RatingBuy$8.00 ➝ $9.50High
1/14/2020Lake Street CapitalBoost Price TargetBuy$10.00 ➝ $15.00Medium
1/14/2020HC WainwrightReiterated RatingBuyHigh
10/31/2019Lake Street CapitalBoost Price TargetBuy$7.00 ➝ $10.00High
10/31/2019Piper Jaffray CompaniesBoost Price TargetOverweight$7.00 ➝ $9.00High
8/28/2019Canaccord GenuityInitiated CoverageBuy$7.00High
8/6/2019HC WainwrightBoost Price TargetBuy$4.00 ➝ $6.00Low
8/5/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$7.00High
2/26/2019HC WainwrightSet Price TargetBuy$4.00Low
1/14/2019HC WainwrightReiterated RatingBuy$4.00High
11/12/2018HC WainwrightReiterated RatingBuy$4.00Low
8/3/2018HC WainwrightReiterated RatingBuy$4.00High
5/11/2018HC WainwrightSet Price TargetBuy$4.00High
3/13/2018HC WainwrightSet Price TargetBuy$4.00High
11/22/2017HC WainwrightReiterated RatingBuy$4.00N/A
10/16/2017Lake Street CapitalInitiated CoverageBuy ➝ Buy$7.00N/A
8/14/2017HC WainwrightInitiated CoverageBuy ➝ Buy$4.00Medium
(Data available from 8/2/2016 forward)
Alphatec logo
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to maximize patient outcomes; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System designed to improve surgical efficiency without compromising accuracy. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; solanas posterior cervico/thoracic fixation system and avalon occipital plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. Further, it develops EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is based in Carlsbad, California.
Read More

Today's Range

Now: $14.88
Low: $14.44
High: $15.25

50 Day Range

MA: $14.71
Low: $13.45
High: $15.99

52 Week Range

Now: $14.88
Low: $4.96
High: $19.36

Volume

465,681 shs

Average Volume

587,771 shs

Market Capitalization

$1.45 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Alphatec?

The following sell-side analysts have issued reports on Alphatec in the last year: Canaccord Genuity, Cowen Inc, HC Wainwright, Lake Street Capital, Piper Sandler, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for ATEC.

What is the current price target for Alphatec?

6 Wall Street analysts have set twelve-month price targets for Alphatec in the last year. Their average twelve-month price target is $16.50, suggesting a possible upside of 10.9%. Lake Street Capital has the highest price target set, predicting ATEC will reach $20.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $12.00 for Alphatec in the next year.
View the latest price targets for ATEC.

What is the current consensus analyst rating for Alphatec?

Alphatec currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATEC will outperform the market and that investors should add to their positions of Alphatec.
View the latest ratings for ATEC.

What other companies compete with Alphatec?

How do I contact Alphatec's investor relations team?

Alphatec's physical mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The medical technology company's listed phone number is 760-431-9286 and its investor relations email address is [email protected] The official website for Alphatec is www.atecspine.com.